APLS Apellis Pharmaceuticals Inc.

41.3
-0.99  -2%
Previous Close 42.29
Open 42.69
Price To Book 18.95
Market Cap 3,091,842,024
Shares 74,863,003
Volume 864,238
Short Ratio
Av. Daily Volume 1,622,993
Stock charts supplied by TradingView

NewsSee all news

  1. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of

  2. Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

    WALTHAM Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously announced

  3. Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public

  4. Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

    WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it has commenced an underwritten

  5. Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16Safety profile of pegcetacoplan

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial plan update due early 2020.
APL-2 subcutaneous
Cold agglutinin disease (CAD)
Phase 1b trial ongoing.
APL-2 PHAROAH
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 enrolment to be completed 1Q 2020.
APL-2 OAKS
Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Phase 3 data met primary endpoint - January 7, 2020.
APL-2 subcutaneous PEGASUS
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
APL-2 PADDOCK
Paroxysmal Nocturnal Hemoglobinuria
Phase 2 initial data presented at ASN November 8, 2019.
APL-2 subcutaneous
Complement-dependent Nephropathies (CDN)
Phase 3 commencement of dosing announced September 3, 2019.
APL-2 PRINCE
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Latest News

  1. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of

  2. Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

    WALTHAM Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously announced

  3. Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public

  4. Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

    WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it has commenced an underwritten

  5. Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16Safety profile of pegcetacoplan

  6. Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease

  7. Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

    CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  8. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky. and WALTHAM Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  9. Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week

    CRESTWOOD, Ky., and WALTHAM Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  10. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM Mass. and CRESTWOOD, Ky., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  11. Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results

    Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed $220 Million Offering of Convertible Senior Notes Due 2026 Cash Position of $434.0

  12. Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

    Company also provides an update on plans in nephrology CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused

  13. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky. and WALTHAM Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  14. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  15. Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  16. Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  17. Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  18. Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

    CRESTWOOD, Ky., and WALTHAM, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds

  19. Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

    CRESTWOOD, Ky., and WALTHAM, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds

  20. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  21. Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308),

  22. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CRESTWOOD, Ky., and WALTHAM Mass, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to

  23. Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

    CRESTWOOD, Ky. and WALTHAM Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to